Carna Biosciences Inc
TSE:4572
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
JP |
Carna Biosciences Inc
TSE:4572
|
7.6B JPY | -4.2 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.8B USD | 33.5 | ||
US |
Danaher Corp
NYSE:DHR
|
184.8B USD | 20.5 | ||
US |
Agilent Technologies Inc
NYSE:A
|
41.8B USD | 32.5 | ||
CH |
Lonza Group AG
SIX:LONN
|
38B CHF | 29.2 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
56.3T KRW | 49.8 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.4B USD | 25.6 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | 26.6 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.8B USD | 39.7 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.8B USD | 26.2 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
18.8B EUR | 52.3 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.